FDA reviewers raise red flags for Amgen cancer vaccine ahead of AdComm

Wednesday's a big day for Amgen ($AMGN), whose dual-acting cancer vaccine/viral therapy is coming up for review by an FDA panel of experts. Agency reviewers have some serious questions about the drug's prospects as a melanoma treatment, however. Among them: Is there clear evidence of a systemic response to the drug, which is designed to spur the immune system as it targets and kills cancer cells? Based on the data presented, that's not so easy to answer, staffers said. More from FierceBiotech

Suggested Articles

The future may be uncertain for AZ’s Imfinzi in first-line lung cancer, but its targeted med Tagrisso now boasts a green light in that setting.

Ultragenyx is back with another FDA nod, this time for Crysvita to treat X-linked hypophosphatemia in patients one year and older.

Roche got a two pieces of good Hemlibra news early this week—and what's good for Hemlibra must be good for Roche.